ABSI
Absci Corp
NASDAQ · Healthcare · Biotechnology · US
$9.65
+4.10%Sep 10, 2026, 19:56 UTC
Eli Lilly is making strategic investments in outside companies such as Absci Corp., which is developing an experimental endometriosis therapy, as part of its expansion into women's health.
Source:Aug 11, 2026, 20:05 UTC
Absci completed a $100 million underwritten offering, including a $40 million strategic investment from Eli Lilly and Company.
Source:Aug 11, 2026, 20:05 UTC
Absci Corporation reported financial and operating results for the second quarter of 2026.
Jun 25, 2026, 15:26 UTC
Absci released positive interim data from its Phase I hair loss study for ABS-201, showing the drug is well tolerated and supports infrequent dosing.
Source:Jun 24, 2026, 20:01 UTC
Eli Lilly invested $40 million in Absci for equity, leading a $50 million funding round.
Source:Jun 24, 2026, 11:55 UTC
Absci Corporation priced a $100 million underwritten offering to support clinical development.